Stockscreener 앱 받기
9.20
2.49%
0.33
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
Market Pulse: Can Kyverna Therapeutics Inc weather a recession2026 Historical Comparison & High Return Stock Watch Alerts - baoquankhu1.vn
[EFFECT] Kyverna Therapeutics, Inc. SEC Filing - Stock Titan
Kyverna Therapeutics enters open market sale agreement with Jefferies dated March 27, 2025SEC filing - marketscreener.com
Kyverna Therapeutics (NASDAQ: KYTX) registers $100M ATM via Jefferies - Stock Titan
HC Wainwright Analysts Increase Earnings Estimates for KYTX - MarketBeat
[144] Kyverna Therapeutics, Inc. SEC Filing - Stock Titan
Late-stage trial testing KYV-101 seeking adults with hard-to-treat gMG - Myasthenia Gravis News
Brokers Issue Forecasts for KYTX FY2027 Earnings - MarketBeat
Goodwin Advises Kyverna Therapeutics On $100 Million Proposed Public Offering Of Common Stock - Mondaq
KYTX SEC FilingsKyverna Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Kyverna Therapeutics files $300M mixed securities shelf - MSN
AI Stocks: Can Kyverna Therapeutics Inc weather a recessionPortfolio Return Report & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Hyperion DeFi (HYPD), Kyverna Therapeutics, Inc. (KYTX) and Medios AG (OtherMEDOF) - The Globe and Mail
KYTX Stock Price, Quote & Chart | KYVERNA THERAPEUTICS INC (NASDAQ:KYTX) - ChartMill
Kyverna Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
KYTX: Miv-cel demonstrates transformative efficacy in autoimmune diseases, targeting SPS and gMG first - TradingView
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
Kyverna Therapeutics (NASDAQ:KYTX) Announces Earnings Results - MarketBeat
Kyverna Therapeutics (NASDAQ: KYTX) files $300M shelf; $100M ATM via Jefferies - Stock Titan
Kyverna Therapeutics 10-K: $161.3M net loss, operating expenses $169.8M; cash runway ≥1 year - TradingView
Kyverna Therapeutics (KYTX) advances SPS, gMG CAR T programs and next-gen cell therapy platform - Stock Titan
[8-K] Kyverna Therapeutics, Inc. Reports Material Event - Stock Titan
Kyverna Therapeutics (KYTX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Kyverna Therapeutics Defeats Claims It Omitted Data From Its IPO - Bloomberg Law News
Kyverna Therapeutics (NASDAQ:KYTX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Investment Report: How much upside does Kyverna Therapeutics Inc have2026 Opening Moves & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Levels Update: What is Kyverna Therapeutics Incs book value per share2026 Big Picture & Daily Volume Surge Signals - baoquankhu1.vn
Kyverna Therapeutics (KYTX) CFO receives new stock options and RSU grant - Stock Titan
Kyverna (KYTX) CEO receives 350,000 options and 58,000 RSUs in equity grants - Stock Titan
Kyverna Therapeutics (KYTX) awards stock options and RSUs to officer Naji Gehchan - Stock Titan
What is Kyverna Therapeutics Incs book value per share2026 Big Picture & Daily Volume Surge Signals - baoquankhu1.vn
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
HC Wainwright & Co. Maintains Kyverna Therapeutics (KYTX) Buy Recommendation - MSN
KYTX stock just surged 11% today – what is the connection with stiff person syndrome? - MSN
William Blair Initiates Coverage of Kyverna Therapeutics (KYTX) with Outperform Recommendation - MSN
Kyverna Therapeutics (KYTX) Price Target Increased by 16.46% to 23.46 - MSN
KYTX: Pivotal miv-cel data in SPS shows disease reversal, with BLA filing and launch planned this year - TradingView
How Kyverna Therapeutics Inc. stock compares to growth peersWeekly Stock Report & Long Hold Capital Preservation Tips - Naître et grandir
Portfolio Recap: Is Kyverna Therapeutics Inc stock trending bullishBreakout Watch & Safe Entry Zone Tips - baoquankhu1.vn
Kyverna to present stiff person syndrome trial data at AAN meeting - Investing.com Australia
Kyverna secures up to $150M loan facility from Oxford Finance - MSN
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 - The Manila Times
Kyverna Therapeutics Announces Presentations on Miv-cel Research at AAN Annual Meeting 2026 - Quiver Quantitative
New cell therapy data in stiff person syndrome set for AAN 2026 - Stock Titan
Aug Fed Impact: What is the Moat Score of Kyverna Therapeutics IncWeekly Profit Recap & Verified Short-Term Trading Plans - baoquankhu1.vn
Director Andrew Craig Miller files initial Form 3 at Kyverna (KYTX) - Stock Titan
Kyverna Therapeutics (KYTX) director awarded options and RSUs in equity grant - Stock Titan
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences - Bitget
Biotech Kyverna lines up March talks at Leerink, Jefferies events - Stock Titan
Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution - Seeking Alpha
P5002025 Year in Review & Long-Term Safe Return Strategies - mfd.ru
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Director at Kyverna Therapeutics (KYTX) granted options and RSUs - Stock Titan
Kyverna Therapeutics (KYTX) director Emany Sravan Kumar files Form 3 - Stock Titan
Is Kyverna Therapeutics Inc. undervalued by DCF analysisMarket Volume Report & AI Powered Trade Plan Recommendations - mfd.ru
1.90%
1.08%
자본화:
|
볼륨(24시간):